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Antipsychotic adherence patterns and health care
utilization and costs among patients discharged
after a schizophrenia-related hospitalization
Michael Markowitz1*, Sudeep Karve2*, Jessica Panish1, Sean D Candrilli2 and Larry Alphs1
Abstract
Background: This study aimed to assess antipsychotic adherence patterns and all-cause and schizophrenia-related
health care utilization and costs sequentially during critical clinical periods (i.e., before and after schizophrenia-
related hospitalization) among Medicaid-enrolled patients experiencing a schizophrenia-related hospitalization.
Methods: All patients aged ≥ 18 years with a schizophrenia-related inpatient admission were identified from the
MarketScan Medicaid database (2004–2008). Adherence (proportion of days covered [PDC]) to antipsychotics and
schizophrenia-related and all-cause health care utilization and costs were assessed during preadmission (182- to
121-day, 120- to 61-day, and 60- to 0-day periods; overall, 6 months) and postdischarge periods (0- to 60-day, 61- to
120-day, 121- to 180-day, 181- to 240-day, 241- to 300-day, and 301- to 365-day periods; overall, 12 months). Health
care utilization and costs (2010 US dollars) were compared between each adjacent 60-day follow-up period after
discharge using univariate and multivariable regression analyses. No adjustment was made for multiplicity.
Results: Of the 2,541 patients with schizophrenia (mean age: 41.2 years; 57% male; 59% black) who were identified,
approximately 89% were “discharged to home self-care.” Compared with the 60- to 0-day period before the index
inpatient admission, greater mean adherence as measured by PDC was observed during the 0- to 60-day period
immediately following discharge (0.46 vs. 0.78, respectively). The mean PDC during the overall 6-month
preadmission period was lower than during the 6-month postdischarge period (0.53 vs. 0.69; P < 0.001). Compared
with the 0- to 60-day postdischarge period, schizophrenia-related health care costs were significantly lower during
the 61- to 120-day postdischarge period (mean: $2,708 vs. $2,102; P < 0.001); the primary cost drivers were
rehospitalization (mean: $978 vs. $660; P < 0.001) and pharmacy (mean: $959 vs. $743; P < 0.001). Following the
initial 60-day period, both all-cause and schizophrenia-related costs declined and remained stable for the remaining
postdischarge periods (days 121–365).
Conclusions: Although long-term (e.g., 365-day) adherence measures are important, estimating adherence over
shorter intervals may clarify the course of vulnerability to risk and enable clinicians to better design adherence/risk-
related interventions. The greatest risk of rehospitalization and thus greater resource utilization were observed
during the initial 60-day postdischarge period. Physicians should consider tailoring management and treatment
strategies to help mitigate the economic and humanistic burden for patients with schizophrenia during this period.
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Background
Schizophrenia is a chronic, severe mental illness character-
ized by psychosis, hallucinations, delusions, and disorganized
speech and behavior. In the United States, approximately
2.4 million (1.1%) adults have schizophrenia in any given
year [1]. The mortality rate in patients with a schizophrenia
diagnosis is 2 to 4 times greater than in the general popula-
tion [2,3]. Additionally, increased rates of comorbidities,
including cardiovascular disorders, diabetes mellitus,
hypertension, hyperlipidemia, and other mental illnesses
(e.g., anxiety, depression, substance abuse), are often
reported among patients with schizophrenia [2,4-6].
These high rates of morbidity and mortality are associ-
ated with high treatment management costs among patients
with schizophrenia. Estimates suggest that schizophrenia-
related direct medical and indirect costs in the United
States are approximately $62 billion annually [7].
Antipsychotics are the mainstay in managing acute
psychotic exacerbations and as maintenance therapy to
prevent relapse among patients with schizophrenia.
Recent studies with multi-year follow-up (over 15 years)
suggest that a subset of patients with schizophrenia show
periods of recovery (defined as “absence of major symp-
toms and adequate psychosocial functioning throughout
the follow-up year”) while not on antipsychotic medica-
tions ([8,9]). Some of the characteristics that were observed
among patients’ not requiring chronic antipsychotic ther-
apy were less vulnerability to anxiety and psychosis, better
neurocognitive skills, and prior experience with periods of
recovery [8]. Even though these studies provided encour-
aging results for a subset of patients, a majority of patients
with schizophrenia (over 60%) were still required to be on
antipsychotic therapy during follow-up. Thus, a consider-
able proportion of patients require chronic antipsychotic
use, in which adherence to the prescribed antipsychotic
regimen is important. Nonadherence to antipsychotic ther-
apy is significantly associated with schizophrenia-related
relapse and hospitalization [10-12]. Among patients hospi-
talized for a schizophrenia relapse, the likelihood of later
rehospitalization is high [13-16]. Furthermore, following
discharge from the hospital, patients with schizophrenia
often face challenges transitioning into the community.
This may result in homelessness, social isolation, un-
employment, and imprisonment [17-20].
Following a schizophrenia-related hospital discharge,
patients with schizophrenia generally are expected to have
an increased risk for rehospitalization and are likely to
incur greater health care costs as they transition to com-
munity care. A prior study [15] suggested that schizophre-
nia patients without an outpatient visit within 60 days
following hospital discharge had a significantly higher risk
for rehospitalization within 90 days of discharge. To ad-
dress this issue, the National Committee for Quality As-
surance, which develops the Healthcare Effectiveness Data
and Information Set (HEDIS) performance measures for
health plans, proposed a measure assessing the rate of
outpatient follow-up among hospital-discharged patients
with schizophrenia [21]. The objective of this measure is
to assess the percentage of individuals enrolled in Medic-
aid who have at least one follow-up outpatient visit within
7 and 30 days of discharge from a schizophrenia-related
hospitalization. It is anticipated that the improved 7- and
30-day follow-up rates expected from this measure should
help lower the rate of rehospitalization, improve overall
health outcomes, and lower the economic burden on the
state Medicaid programs. Thus, adequate and timely med-
ical follow-up after hospital discharge is important in
potentially lowering the rate of readmission and the asso-
ciated economic burden. However, limited data exist that
evaluate antipsychotic adherence patterns, heath care
utilization, and the associated economic burden followed
sequentially across smaller high-risk postdischarge follow-
up periods (i.e., 60 days) among schizophrenia patients.
The objective of this study was to assess antipsychotic ad-
herence patterns and all-cause and schizophrenia-related
health care utilization and costs sequentially during crit-
ical high-risk postdischarge periods (i.e., before and after
schizophrenia-related hospitalization) for patients experi-
encing a schizophrenia-related hospitalization. Findings of
this analysis may help with efficient resource allocation
and in designing interventions specifically to target this
high-risk population.
Methods
Study design and data source
This was a retrospective, longitudinal cohort analysis of
the MarketScan Medicaid Multi-State database for the
years 2004 through 2008. For confidentiality purposes,
the researchers were not aware of which US 11 states
had contributed data to this database. Data included med-
ical (i.e., hospital inpatient, hospital outpatient, emergency
department [ED], physician office, long-term care, and an-
cillary care) and prescription drug claims for Medicaid-
enrolled individuals. The medical claims data included
information on date of service, physician diagnosis (up
to 15 primary and secondary diagnoses), primary and
secondary procedures conducted, length of stay (for in-
patient, ED, and long-term care settings only), and charges
associated with the claim. The pharmacy claims data in-
cluded National Drug Code, days’ supply, dosage form,
therapeutic class of the drug, and charges associated with
the claim. In addition to medical and pharmacy claims, the
database also contained an eligibility file that included in-
formation on patient demographic characteristics (e.g., age,
gender, health coverage, and race) and periods of Medicaid
enrollment. Individuals in the medical, pharmacy, and eli-
gibility files could be linked and longitudinally followed
using a unique encrypted identification number.
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The conduct of this study was approved by the Institu-
tional Review Board at RTI International.
Patient selection
The following inclusion and exclusion criteria were used
in the selection of study cohort:
 Inclusion criteria (all of which must have been met)
– Patients with an inpatient admission with primary
schizophrenia diagnosis (i.e., International
Classification of Diseases, 9th Revision, Clinical
Modification [ICD-9-CM] diagnosis code 295.xx,
except 295.x7) between July 1, 2004, and
December 31, 2007, and associated hospital
discharge on or before December 31, 2007.
– Continuous Medicaid enrollment during the
6-month period before the index admission
date (i.e., date of the first observed inpatient
admission), hereafter referred to as the “preindex
period”; during the index inpatient admission; and
during the 12-month period after the index
discharge date (i.e., date of discharge associated
with the index admission), hereafter referred to as
the “postindex period.”
– In addition to the index schizophrenia admission,
at least one outpatient or physician office visit
with a primary schizophrenia diagnosis or two or
more prescription claims for first- or second-
generation antipsychotic medications during the
preindex and postindex periods.
 Exclusion criteria
– Patients with schizophrenia-related inpatient
admissions (secondary diagnosis) during the
preindex period. Because prior schizophrenia-related
inpatient admission has been associated with a high
risk of schizophrenia-related rehospitalization, this
exclusion criterion ensured that each selected
patient had a uniform-length (i.e., 6 months) clean
period during which there was no evidence of a
schizophrenia-related inpatient admission.
– Patients with at least one primary diagnosis claim
for bipolar or schizoaffective disorder or more
than two primary diagnoses claims for unipolar
disorder during the postindex period. This
criterion was primarily considered to lower the
likelihood of misclassification of schizophrenia
with other mental health conditions.
– Patients aged 17 years or younger at their index
admission date and patients aged 65 years or
older at their follow-up end date.
– Patients with dual eligibility (i.e., Medicaid and
Medicare) were excluded because patients with
coverage under both plans would likely have
incomplete claims history in the data recorded
for each plan, and as such, certain events may
not be reflected in their Medicaid claims record.
– Patients without mental health and substance
abuse coverage.
A schematic representation of the study period is in-
cluded in Figure 1.
Study measures
Antipsychotic adherence patterns
Adherence to antipsychotic medications was evaluated on a
shorter-term basis: sequentially over time for 60-day inter-
vals starting 6 months before hospitalization and for up to
12 months after discharge. Adherence also was evaluated
on a longer term-basis: comparing the full 6 months before
and the full 6 months after index hospitalization discharge.
Adherence to antipsychotic treatment was evaluated by the
proportion of days covered (PDC) measure [22-24]. The
PDC method assesses drug availability for each day of the
study period, rather than cumulative exposure as assessed
by the commonly used medication possession ratio. Be-
cause the study included distinct time intervals of evalu-
ation (e.g., 0- to 60-day and 61- to 120-day periods
following the index discharge date), adherence measure-
ment for each day during the study period was considered
more appropriate than measuring cumulative adherence.
The following formula was used to calculate PDC:
PDC ¼ Total days of drug availability days0supplyð Þin the
period of evaluation ðNumber of days in the
period ofevaluation‐Number of days hospitalized
during the period of evaluationÞ:
Figure 1 Schematic representation of study periodsa.
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Medicaid claims data do not include details on medi-
cations provided during an inpatient stay. Thus, an as-
sumption was made that patients received a full supply
of their antipsychotic medications during a hospital stay
and were 100% adherent to their supplied medications
during the stay, and days hospitalized were subtracted
from the denominator [22,25]. Moreover, because the
data did not include details on days’ supply for anti-
psychotic depot preparations (i.e., risperidone, fluphen-
azine, and haloperidol) administered in an office setting,
the following approved dosage durations were used as a
proxy for the days’ supply for these treatments:
 Risperidone long-acting injection: 2 weeks
 Haloperidol long-acting injection: 4 weeks
 Fluphenazine long-acting injection: 4 weeks
Patients with a PDC value of less than 0.8 (i.e., < 80%
adherence) were classified as nonadherent, whereas pa-
tients with a PDC value of 0.8 or greater were classified
as adherent [26]. PDC was assessed for the preindex pe-
riods (i.e., 182- to 121-day, 120- to 61-day, and 60- to
0-day periods; and 6 months overall) and postindex pe-
riods (i.e., 0- to 60-day, 61- to 120-day, 121- to 180-day,
181- to 240-day, 241- to 300-day, and 301- to 365-day pe-
riods; and 12 months overall).
Health care utilization and costs
Overall (i.e., all-cause) and schizophrenia-related health
care utilization and costs were assessed (both unadjusted
and covariate-adjusted analyses) on a shorter-term basis:
sequentially over time for 60-day intervals during the
12 months after discharge. Resource use and costs were
also evaluated on a longer term-basis: comparing the full
6 months before the index admission and the full 6 months
after index hospitalization discharge. Schizophrenia-related
utilization was defined as medical claims with a primary
diagnosis for schizophrenia (i.e., ICD-9-CM: 295.xx, except
295.7x) or pharmacy claims for first- or second-generation
antipsychotics. Both all-cause and schizophrenia-related
health care utilization and costs were assessed for various
care settings: inpatient, outpatient, physician office, ED,
pharmacy, and other ancillary care. Health care utilization
was further documented as follows: 1) the percentage of
patients with one or more claims for the aforementioned
care settings; 2) the number of unique inpatient admis-
sions; 3) the mean number of inpatient days; and 4) other
categories of resource use, including the following: number
of outpatient, physician office, ED, and other ancillary care
visits and pharmacy claims, each assessed separately.
Costs associated with health care utilization were
assessed and adjusted to 2010 US dollars, using the
medical care component of the Consumer Price Index.
In cases where an inpatient stay spanned two or more
follow-up time periods, a length of stay (LOS) was
assigned to each follow-up period based on the number
of days the patient was in the hospital during each
period. Similarly, a per-day cost (i.e., total cost for the
inpatient episode ÷ LOS) was calculated for each in-
patient episode. Costs then were assigned to each
follow-up period on the basis of the LOS in that period.
Statistical analyses
All statistical analyses were conducted using the SAS
(version 9.2) statistical software package (SAS Institute
Inc., Cary, North Carolina). Descriptive statistics were
generated for all study measures, which included fre-
quency distributions for categorical variables and mean
values and standard deviations (SDs) for continuous
variables. Paired t tests were used to compare univari-
ate (i.e., unadjusted) differences in continuous measures
of interest (e.g., the number of inpatient admissions), and
McNemar’s test was used for categorical measures of
interest (e.g., had an inpatient admission) between each
adjacent postindex period. No adjustment was made for
multiplicity.
Multivariable regression analyses were conducted to
assess differences in all-cause and schizophrenia-related
health care utilization and costs between each adjacent
postindex period, after adjusting for patient baseline
demographic and clinical characteristics. The primary
independent variable for this study was an indicator for
60-day follow-up periods. All the study measures were
compared between each adjacent 60-day follow-up period,
using an indicator for each follow-up period. For example,
comparing inpatient costs during the 0- to 60–day period
versus 61- to 120–day period, the study period indicator
was considered 1 if the study period was 61- to 120-days
and 0 if the study period was 0- to 60-days (i.e., reference
category).
Other covariates considered for this study include pa-
tient characteristics (i.e., age, gender, race, health plan
type, basis of Medicaid eligibility, mental health and sub-
stance abuse coverage, and index hospitalization dis-
charge status) and the baseline comorbidity burden
assessed using the Deyo-adapted Charlson Comorbidity
Index score [27]. Finally, prior costs have been shown to
predict follow-up heath care utilization and costs [26]
and have been previously used as a proxy for disease se-
verity [28,29]. Consequently, the preindex period’s all-
cause total health care costs and the sum of preindex
period costs were assessed and used as a proxy for dis-
ease severity.
The type of regression analysis employed depended on
the nature of the outcome that was assessed. For count
data (e.g., number of physician office visits), repeated mea-
sures Poisson or negative binomial regression models
were used. The selection of Poisson or negative binomial
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regression models was based on the model fit, assessed
using a Pearson chi-square test. We estimated incidence
rate ratios (IRRs) and corresponding 95% confidence in-
tervals (CIs) for the count data models. IRRs based on
these models indicated an increase (IRR > 1) or decrease
(IRR < 1) in the rate of utilization of the measure being
modeled during a follow-up period, compared with the
adjacent follow-up period. Additionally, repeated mea-
sures logistic regression models were used for dichotom-
ous measures (e.g., had a physician office visit), where the
odds ratio (OR) based on the model indicated the in-
creased (IRR > 1) or decreased (IRR < 1) likelihood of the
event during a follow-up period, compared with the adja-
cent follow-up period.
Finally, for cost outcomes (e.g., all-cause physician of-
fice visits costs), repeated measures generalized linear
models (GLMs) with a log-link function and gamma dis-
tribution were used. In comparison with ordinary linear
regression involving log-transformed cost data, GLM
methodology offered several advantages, primarily be-
cause it estimates covariate-adjusted predicted mean
costs on a dollar scale, which then can be compared
using the Student t test [30,31]. The GLM methodology
avoids potential biases resulting from the Duan smearing
method for retransforming the predicted coefficient
from log-transformed cost data [30,32].
Results
Baseline characteristics
Additional file 1 presents the sample attrition chart, and
baseline patient characteristics are presented in Table 1.
Of the 2,541 patients with schizophrenia who met all
study inclusion criteria, 56.7% were males and over 59%
were black. The mean (SD) age of the study cohort was
41.17 (12.18) years. A majority (61.3%) of patients were
enrolled in a fee-for-service health plan. Over 90% had
“blind/disabled individual” as the reason for Medicaid
eligibility. Over 88% of the study sample had discharge
disposition coded as “discharged to home self-care.”
Antipsychotic therapy adherence
The overall 6-month preindex period mean (SD) PDC
was lower than the 6-month postindex period mean
PDC (0.53 [0.39] vs. 0.69 [0.32]; P < 0.001) (Table 2).
Similarly, a greater proportion of patients was adherent
(PDC ≥ 80%) to antipsychotic therapy during the postindex
period than during the preindex period (51.2% vs. 38.6%;
P < 0.001). Over each adjacent 60-day increment in the
6-month preindex period, a decline in the adherence
rate was observed. The mean adherence rate was 63%
during the 182- to 121-day period, which declined to
50% during the 121- to 61-day period and to 46% dur-
ing the 60- to 0-day period (just prior to the index in-
patient admission). In contrast to the 60- to 0-day
period, the adherence rate considerably improved dur-
ing the 0- to 60-day period (immediately following index
hospital discharge) (46% vs. 78%; P < 0.001). However, the
adherence rate declined by 15% during the 61- to 120-day
postdischarge period, compared with the 0- to 60-day
postdischarge period (P < 0.001), then remained relatively
stable during the remaining follow-up periods (range:
58%-63%).
Unadjusted health care utilization and costs
Additional files 2 and 3 present details on unadjusted
health care utilization and associated costs during the
follow-up periods, by care settings. Because health care
utilization and costs were considerably higher during the
initial 0–60 day period compared with the other 60-day
follow-up periods, the following results focus primarily
on the 0–60 day versus the 61–120 day period.
Unadjusted schizophrenia-related utilization and costs
A significantly greater proportion of patients had a
schizophrenia-related inpatient admission (13.9% vs.
8.3%; P < 0.001) during the 0- to 60-day period than
during the 61- to 120-day postdischarge period. The
proportion of patients with a schizophrenia-related
hospitalization significantly declined during the 61- to
120-day postdischarge period (13.9% vs. 8.3%; P < 0.001),
compared with the 0- to 60-day postdischarge period; the
proportion declined but did not differ statistically during
the remaining postdischarge follow-up periods (range:
6.2%-7.9%; P > 0.05 for all comparisons) (see Additional
file 2). Schizophrenia-related utilization was also signifi-
cantly greater for other care settings, including hospital
outpatient visits (P < 0.001), ED visits (P = 0.009), and
pharmacy claims (P < 0.001) during the 0- to 60-day
postdischarge period than during the 61- to 120-day
postdischarge period. Schizophrenia-related total medical
costs were significantly greater during the 0- to 60-day period
than during the 61- to 120-day postdischarge period (mean:
$2,708 vs. $2,102; P< 0.001), with rehospitalization (mean:
$978 vs. $660; P < 0.001) and pharmacy (mean: $959 vs.
$743; P < 0.001) costs being the two primary drivers of
these increased costs (Figure 2 and Additional file 3). Fi-
nally, schizophrenia-related total medical costs (mean:
$6,931 vs. $3,442; P < 0.001) were significantly greater dur-
ing the 6-month postdischarge date period compared with
the 6-month preindex period.
All-cause utilization and costs
A significantly greater proportion of patients had an all-
cause hospitalization (17.5% vs. 11.3%; P < 0.001) during
the 0- to 60-day period than during the 61- to 120-day
postdischarge period. All-cause hospitalization costs were
higher during the initial 0–60 day period (mean: $1,387)
compared with the 61–120 day period (mean: $1,008;
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Table 1 Baseline characteristics
Characteristic All patients
Total Sample 2,541 100.00
Gender, n (%)
Male 1,440 56.67
Female 1,101 43.33
Age at Index Admission Datea
Mean (SD) yrs. 41.17 12.18
Age distribution (years), n (%)
18-24 315 12.40
25-34 493 19.40
35-44 578 22.75
45-54 763 30.03
55-64 392 15.43
Race/Ethnicity, n (%)
White 807 31.76
Black 1,509 59.39
Hispanic 16 0.63
Other 209 8.23
Health Coverage, n (%)
Fee-for-service 1,557 61.28
Capitated 984 38.72
Basis of Medicaid Eligibility, n (%)
Blind/disabled individual 2,393 94.18
Adult (not based on unemployed status) 69 2.72
Child (not child of unemployed adult, not foster care child) 65 2.56
Otherb 14 0.55
Hospital Discharge Status, n (%)
Discharged to home self-care 2,254 88.71
Transfer to skilled nursing facility 47 1.85
Transfer to other facility 122 4.80
Left against medical advice 14 0.55
Other alive status 1 0.04
Not yet discharged/transferred 26 1.02
Missing/unknown 77 3.03
Preindex Periodc All-Cause Health Care Costs
Mean (SD) $8,162.64 $10,793.97
Preindex Period Depot Antipsychotic Used, n (%)
Yes 126 4.96
No 2,415 95.04
Preindex Period Charlson Comorbidity Index Score
Mean (SD) 0.87 1.56
SD standard deviation.
aThe date for the first observed schizophrenia-related inpatient admission defined the index admission date.
bOther included foster-care child, aged individual, and eligibility status unknown.
cThe 6-month period prior to the index admission date defined the preindex period.
dDefined as at least 1 claim for depot antipsychotic preparation, including risperidone, fluphenazine, and haloperidol.
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P < 0.001) and remained stable during the remaining
follow-up period (range of means: $886-$964; P > 0.05
for all comparisons). Similarly, compared with the 0-
to 60-day postdischarge period, all-cause costs (mean:
$4,514) declined in the 61- to 120-day postdischarge
period (mean: $3,738) and remained relatively stable
(range of means: $3,577 to $3,984) during the remaining
postdischarge periods (see Additional file 3). Finally, all-
cause total medical costs (mean: $12,028 vs. $8,163;
P < 0.001) were significantly greater during the 6-month
postdischarge date period compared with the 6-month
preindex period, respectively.
Table 2 Adherencea to antipsychoticb therapy among medicaid-enrolled schizophrenia patients
Adherence Preindex period
182-121 Days 121-61 Days 60-0 Days Overall 6 Months
PDCc
Mean (SD) 0.63 0.39 0.50 0.44 0.46 0.45 0.53 0.39
PDC Categorical (80% Threshold), n (%)
Nonadherent total (PDC < 80%) 1,227 48.29 1,483 58.36 1,572 61.87 1,560 61.39
Adherent total (PDC≥ 80%) 1,314 51.71 1,058 41.64 969 38.13 981 38.61
Total 2,541 100.00 2,541 100.00 2,541 100.00 2,541 100.00
Adherence Postindex period
0-60 Days 61-120 Days 121-180 Days Overall 6 Months
PDCc
Mean (SD) 0.78 0.27 0.63 0.40 0.62 0.42 0.69 0.32
PDC Categorical (80% Threshold), n (%)
Nonadherent total (PDC < 80%) 940 36.99 1,204 47.38 1,183 46.56 1,240 48.80
Adherent total (PDC≥ 80%) 1,601 63.01 1,337 52.62 1,358 53.44 1,301 51.20
Total 2,541 100.00 2,541 100.00 2,541 100.00 2,541 100.00
PDC proportion of days covered, SD standard deviation.
aAdherence measured during the 6-month period before the index inpatient admission and the 6-month period after the index discharge date.
bAntipsychotic therapy included first- and second-generation antipsychotic medications.
cPDC = total days of drug availability ÷ (days in study period – days hospitalized).
Figure 2 Follow-up period unadjusted health care costs,a by care setting. A. Unadjusted all-cause cause health care costs; B. Unadjusted
Schizophrenia-related health care costs. ED = emergency department. a The 12-month period following the index discharge date defines the
postindex period.
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Risk-adjusted health care utilization and costs
Figure 3 presents risk-adjusted IRRs for all-cause and
schizophrenia-related health care utilization, by care set-
tings, for the 0- to 60-day and the 61- to 120-day
postdischarge periods. Similarly, Figure 4 presents covar-
iate-adjusted predicted all-cause and schizophrenia-
related health care costs, by individual care settings, for
the 0- to 60-day and the 61- to 120-day postdischarge
periods.
Adjusted schizophrenia-related utilization and costs
The covariate-adjusted rate of schizophrenia-related
rehospitalization was significantly lower (IRR: 0.61; 95%
CI: 0.52-0.72; P < 0.001) during the 61- to 120-day
postdischarge period than during the 0- to 60-day
postdischarge period (Figure 2). Other covariate-adjusted
period comparisons are presented in Additional file 4. The
rate of schizophrenia-related rehospitalization did not dif-
fer significantly for the remaining postdischarge periods,
including 121 to 180 days (IRR: 0.94; P = 0.469; compared
with 61–120 days), 181 to 240 days (IRR: 0.89; P = 0.189;
compared with 121–180 days), 241 to 300 days (IRR:
0.93; P = 0.420; compared with 181–240 days) and 301
to 364 days (IRR: 0.98; P = 0.876; compared with 241–
300 days). Schizophrenia-related costs were lower across
various care settings, including pharmacy, physician office,
hospital outpatient, and inpatient care, during the 61- to
120-day postdischarge period compared with the 0- to
60-day postdischarge period (Figure 4).
Adjusted all-cause utilization and costs
The all-cause rehospitalization rate was significantly
lower (IRR: 0.664; 95% CI: 0.563-0.736; P < 0.001) dur-
ing the 61- to 120-day postdischarge period than dur-
ing the 0- to 60-day postdischarge period, after adjusting
for baseline covariates. After adjusting for covariates, com-
pared with the 0- to 60-day postdischarge period, the
predicted all-cause costs were significantly less for
various care settings, including pharmacy (mean: $1,438
vs. $1,246; P < 0.001), physician office (mean: $385 vs.
$378; P < 0.001), hospital outpatient (mean: $478 vs. $441;
P < 0.001), and inpatient (mean: $7,676 vs. $7,336; P <
0.001) costs during the 61- to 120-day postdischarge
period, respectively.
Discussion
To the best of our knowledge, this is the first study to
assess trends in antipsychotic adherence, health care
utilization, and costs sequentially across smaller high-
risk postdischarge periods among patients experiencing
a schizophrenia-related inpatient admission. A decline in
the antipsychotic medication adherence rate from 63%
Figure 3 Risk-adjusted IRRs for 61-120 day period post inpatient discharge, by care setting. A. IRRs for all-cause cause health care
utilization; B. IRRs for Schizophrenia-related health care utilization. ED = emergency department; IRR = incident rate ratio. a IRR based on negative
binomial regression model, adjusted for study period (61-120 day period indicator [0-60 day period reference]) and other relevant covariates
(i.e., gender, race, age, CCI score, plan type, discharge status, antipsychotic adherence, preindex period health care cost. Graph presents IRR
and corresponding 95% confidence intervals).
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(during the 182- to 121-day preadmission period) to
46% (during the 60- to 0-day preadmission period) prior
to the first observed schizophrenia-related hospital admis-
sion was observed. The lower antipsychotic adherence of
46% observed during the 60- to 0-days preadmission
period prior to the first observed schizophrenia-related
hospital admission may have been one of the reasons for
the hospital admission. Following hospital discharge,
the risk of rehospitalization was significantly greater in
the 0- to 60-day postdischarge period than in the 61- to
120-day postdischarge period. However, the risk of
rehospitalization did not differ significantly in the
remaining postdischarge periods. Similarly, the overall
mean schizophrenia-related health care cost for the
12-month postdischarge period was $12,836; over 21%
of this amount was incurred in the 0- to 60-day
postdischarge period, and approximately 16% was in-
curred during each remaining 60-day postdischarge
period.
Several studies have previously evaluated the association
between adherence to antipsychotics and the risk for
hospitalization among Medicaid enrollees [33-37]. Find-
ings of these studies suggested that patients nonadherent
(< 80%) to antipsychotic therapy have a greater likelihood
of hospitalization than adherent patients. In comparison
with our study, which assessed adherence at smaller
intervals (i.e., 60 days), most of the published studies we
found have assessed adherence over a longer follow-up
period (e.g., 365 days). Prior study findings suggested that,
compared with continuous medication availability, a small
gap of 10 days following a missed prescription refill was
associated with an increased risk of schizophrenia-related
hospitalization (hazard ratio: 1.77; 95% CI: 1.16-2.71) [38].
An earlier study reported that patients with schizophrenia
who experienced a therapy gap of 11 to 30 days (OR: 2.8;
95% CI: 1.8-4.6; P < 0.001) or 30 days or more (OR: 3.9;
95% CI: 2.5-6.5; P < 0.001) had significantly greater risks
for hospitalization than did patients without therapy gaps
[39]. Similarly, our study, assessing adherence over small
intervals, found that adherence to antipsychotics was
lower (PDC 46%) during the 60- to 0-day period prior to
hospital admission, and this lower adherence may have
been one of the factors associated with the hospital admis-
sion. The disadvantage of measuring adherence over a
long follow-up period is that it masks shorter intervals
during which a patient may not be adherent to the pre-
scribed medications and which can result in an inpatient
admission. For example, if a nonhospitalized patient refills
his or her prescribed medication every 30 days for
10 months (300 days’ drug supply) but then does not refill
the medication for the next 2 months, using a 1-year
follow-up period in the PDC calculation, the medication
Figure 4 Adjusted health care costs during 0-60 day and 61-121 day periods post inpatient discharge, by care setting. A. Adjusted all-
cause cause health care costs; B. Adjusted Schizophrenia-related health care costs. Predicted costs estimates based on generalized linear models,
and corresponding P values based on paired t test (aP < 0.001; bP = 0.039).
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adherence rate for this patient would be 82% (= 300 days’
drug supply ÷ 365 days). This patient will be considered
adherent for the year, using an 80% threshold, but may be
at an increased risk for hospitalization, given the 60-day
gap in therapy adherence. With increasing emphasis on
identifying high-risk patients for targeted pharmacist in-
terventions (e.g., medication therapy management), meas-
uring medication adherence over smaller intervals may
serve as an efficient tool in identifying high-risk patients
for these interventions [40].
A second key finding of our study was the identifica-
tion of a high-risk postdischarge period (i.e., 60 days
postdischarge) during which a patient has an increased
risk for rehospitalization and incurs greater health care
costs. Prior studies have suggested that patients with
schizophrenia experiencing hospitalization had a greater
likelihood of rehospitalization following hospital dis-
charge, with the first hospitalization event being a sig-
nificant predictor of the rehospitalization event [13-16].
Consequently, patients experiencing rehospitalization
have approximately 5 times greater health care costs
(mean: $50,986 vs. $10,352) than patients without a
rehospitalization [13]. However, none of these studies have
identified the high-risk period(s) during which increased
risk of rehospitalization exists. Information about the
high-risk period during which the patient has an increased
risk for rehospitalization is important from a patient man-
agement perspective, primarily because physicians and
other health care providers may design treatment strat-
egies for the critical period, which may in turn help reduce
the risk of rehospitalization and the associated costs.
Our analysis found that the proportion of patients with
schizophrenia-related rehospitalization was highest in
the 0- to 60-day period (13.9%) following hospital dis-
charge than in any other follow-up 60-day period
(range: 6.2%-8.3%). Thus, our findings are an import-
ant initial step toward the identification of a high-risk
period during which hospital-discharged patients with
schizophrenia have a higher risk of rehospitalization
and are likely to incur higher health care costs.
Prior studies have defined recovery among hospital-
discharged patients with schizophrenia as the absence of
positive or negative symptoms and no rehospitalization
within the year following hospital discharge [8]. Thus, pre-
vention of rehospitalization evaluated in this study is a
critical component of recovery among patients with
schizophrenia. Prior research suggests that interventions
such as communication between inpatient staff and out-
patient physicians’, patients’ initiating outpatient programs
prior to discharge, and involvement of patient family
during the hospital stay help in the effective transition
of patients from inpatient to outpatient care settings
and improve clinical outcomes [41,42]. Since hospital-
discharged patients with schizophrenia likely differ on
various factors such as duration of disease, severity,
availability of family and social support, and access to
follow-up care, designing a patient-specific discharge
and monitoring plan is critical. With our study provid-
ing empirical data on the critical period, additional re-
search is required to assess if patient-specific discharge
plans and monitoring during this critical period helps
reduce the rate of rehospitalization and improve pa-
tient recovery.
Furthermore, among patients requiring antipsychotic
therapy to control relapses, adherence to the prescribed
therapy is critical. This study provides evidence for using
short-term adherence as a tool for identifying patients at
high risk for an inpatient admission. Interventions such
as routine counseling (e.g., pharmacists, nurse, family
members) and simplifying dosing regimens (e.g., once-
daily, long-acting injectables) may help improve therapy
adherence among these high risk patients. For example,
a review of interventions aimed to improve adherence to
antipsychotics concluded that a combination of educa-
tional (e.g., lecture series, drug data sheet upon discharge),
behavioral (e.g., weekly group sessions), and affective
(e.g., assertive community treatment) interventions helps
improve adherence to prescribed therapy [43].
Several limitations must be considered when interpreting
these study findings. First, ICD-9-CM diagnosis codes were
used in the selection of patients with schizophrenia; coding
inaccuracies or misclassification of other mental health
conditions (e.g., bipolar disorder) as schizophrenia may
lead to misidentification of patients with schizophrenia.
However, to reduce the likelihood of misidentification of
patients, several measures were undertaken, including 1)
the requirement that the patient have at least two medical
claims with a diagnosis of schizophrenia or 2) the require-
ment that the patient have at least one claim with a
primary diagnosis of schizophrenia and two prescrip-
tion claims for antipsychotics, and 3) the exclusion of
patients with other similar mental health conditions,
including schizoaffective, bipolar, and unipolar disor-
ders. Additionally, prior studies have suggested differ-
ences in patient characteristics and outcomes among
patients with schizoaffective disorder compared with
patients with schizophrenia [44-46]. Thus, separate
studies assessing health care utilization and costs dur-
ing the post-discharge critical period are required in a
schizoaffective disorder population rather than consid-
ering the common practice of including these patients
as a part of schizophrenia population [47,48]. Second,
this analysis was limited to Medicaid enrollees, and
findings may not be generalizable to individuals en-
rolled in other federal (e.g., Medicare, Veterans Affairs)
or commercial health plans or to individuals without
health insurance. Furthermore, several inclusion and
exclusion criteria were used to ensure that all the
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selected patients had adequate and uniform follow-up
data, such as requiring patients to have continuous
Medicaid enrollment during the entire study period
and excluding patients with dual Medicare and Medic-
aid eligibility and patients without mental health
coverage. Because of these criteria, a subset of Medic-
aid enrollees was used; hence our findings may not be
generalizable to all Medicaid enrollees with schizo-
phrenia. Specifically, a majority (> 50%) of patients
were lost either because they did not have continuous
Medicaid enrollment during the study period or because
they had other psychiatric conditions (schizoaffective, bi-
polar, and unipolar disorders). The continuous enrollment
criterion was imposed to ensure that the selected patients
had adequate and uniform in length preindex and
postindex follow-up data. Similarly, patients with other
similar psychiatric conditions were excluded because
presence of these conditions would in itself be associ-
ated with greater risk of rehospitalization; thus, an at-
tempt was made to limit the study population to a
clean schizophrenia patient cohort. Third, a Medicaid
payer’s perspective was considered in assessing direct
cost estimates; direct medical costs were calculated
using the amount paid by Medicaid to service providers
for the delivery of services. Thus, the data did not account
for patients’ out-of-pocket expenses (e.g., co-insurance,
copayment), which would have the effect of underestimat-
ing the total direct cost burden for the study cohort.
Moreover, indirect costs such as productivity losses and
caregiver costs were not assessed; therefore, additional re-
search is required to estimate the indirect cost burden for
various clinically relevant postdischarge periods among
patients with a schizophrenia-related inpatient admission.
Fourth, assessment of adherence to prescribed therapy
using an administrative claims database is based on the
“days supply” recorded on outpatient pharmacy claims.
However, these pharmacy claims only represent prescrip-
tions filled and do not indicate if the medication was con-
sumed. Additionally, these data do not include details on
any medication samples received by the patient at a
physician office, which may result in underestimation
of medication adherence. Finally, the MarketScan Me-
dicaid Multistate database did not include information
on certain clinical and demographic factors, such as
medication-related adverse events, employment status,
education level, income, and receipt of other interventions
such as psychoeducation, or psychosocial rehabilitation
which may have an effect on access to medical care, ad-
herence to prescribed therapy and resource utilization and
costs.
Conclusions
This study provides insights into two key aspects of pa-
tients experiencing schizophrenia-related hospitalization.
First, assessing adherence to antipsychotic medications
over smaller intervals may serve as a helpful tool in identi-
fying patients at increased risk for hospitalization. Identi-
fying these high-risk patients and designing adherence-
related interventions may help reduce the likelihood of
hospital admissions and in turn may reduce the associated
downstream costs. Second, our study findings suggest that
hospital-discharged schizophrenia patients are at an in-
creased risk for rehospitalization during the initial 60-day
period as they transition to the community setting, which
in turn exerts a greater economic burden on the Medicaid
system. Past studies have suggested that restrictions on
length of hospital stay as a cost-containment measure in-
creased the likelihood of rehospitalization within 60 days
of discharge among mental health patients [49,50]. How-
ever, further research is required to better understand
additional factors associated with increased health care re-
source consumption during this initial 60-day period fol-
lowing discharge and may aid physicians in crafting
tailored management and treatment strategies to help
mitigate the economic and humanistic burden of illness in
patients with schizophrenia.
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